Pacific Biosciences of California, Inc.
PACBPacific Biosciences of California, Inc. develops and commercializes advanced DNA sequencing systems and technologies. Known for its long-read sequencing capabilities, the company provides solutions for genomic research, clinical applications, and agricultural research, enabling detailed and accurate analysis of complex genetic structures.
Company News
The global genomics data analysis market is projected to grow from $6.85 billion in 2024 to $28.74 billion by 2034, driven by advancements in sequencing technologies, personalized medicine demand, and AI-driven analytics.
Ark Invest has been adding to its positions in Amazon, GitLab, and Pacific Biosciences of California. Amazon's stock hit an all-time high last month, and analysts see further upside. GitLab's recent financial results exceeded expectations, while Pacific Biosciences has struggled but Ark remains a believer in its long-term potential.
Cathie Wood, the famed investor, is doubling down on her conviction bets in biotechnology, artificial intelligence, and electric vehicles, including Tesla, Pacific Biosciences, and Crispr Therapeutics.
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB) in the last three months. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish In...
